

# Mark B Faries

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020193/publications.pdf>

Version: 2024-02-01

126  
papers

9,007  
citations

71061

41  
h-index

42364

92  
g-index

128  
all docs

128  
docs citations

128  
times ranked

7881  
citing authors

#	ARTICLE	IF	CITATIONS
1	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
2	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 599-609.	13.9	1,203
3	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	13.9	1,087
4	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
5	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 399-413.	0.8	190
6	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
7	The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). <i>Annals of Surgical Oncology</i> , 2010, 17, 3324-3329.	0.7	177
8	Incidence of Sentinel Node Metastasis in Patients With Thin Primary Melanoma (#1 mm) With Vertical Growth Phase. <i>Annals of Surgical Oncology</i> , 2000, 7, 262-267.	0.7	173
9	Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+ T-Cell Function in Melanoma Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 3826-3835.	0.8	168
10	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555.	0.7	155
11	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
12	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. <i>Clinical Cancer Research</i> , 2008, 14, 638-645.	3.2	141
13	Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 680-688.	0.7	138
14	Practice Patterns and Outcomes for Anorectal Melanoma in the USA, Reviewing Three Decades of Treatment: Is More Extensive Surgical Resection Beneficial in All Patients?. <i>Annals of Surgical Oncology</i> , 2010, 17, 40-44.	0.7	131
15	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018, 25, 356-377.	0.7	130
16	Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 2251-2261.	0.4	126
17	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319.	0.7	117
18	Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma. <i>Archives of Surgery</i> , 2008, 143, 892.	2.3	116

#	ARTICLE	IF	CITATIONS
19	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3991-4000.	0.7	102
20	Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials. <i>Annals of Surgical Oncology</i> , 2013, 20, 2590-2599.	0.7	101
21	Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. <i>Cancer Discovery</i> , 2019, 9, 82-95.	7.7	100
22	Improved Survival for Stage IV Melanoma From an Unknown Primary Site. <i>Journal of Clinical Oncology</i> , 2009, 27, 3489-3495.	0.8	95
23	Age-Related Lymphatic Dysfunction in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 1548-1552.	0.7	92
24	Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy. <i>Journal of the American College of Surgeons</i> , 2013, 217, 27-34.	0.2	86
25	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. <i>Annals of Surgery</i> , 2012, 255, 357-362.	2.1	83
26	Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 7029-7035.	3.2	82
27	Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. <i>Annals of Surgical Oncology</i> , 2011, 18, 3593-3600.	0.7	78
28	Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3819-3826.	0.8	77
29	Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 716-720.	1.2	75
30	mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads. <i>Clinical Chemistry</i> , 2009, 55, 757-764.	1.5	71
31	A Phase 2 Study of 99mTc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 961-969.	0.7	68
32	Sentinel node biopsy in melanoma: Technical considerations of the procedure as performed at the John Wayne Cancer Institute. <i>Journal of Surgical Oncology</i> , 2010, 101, 669-676.	0.8	65
33	Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development. <i>Blood</i> , 2001, 98, 2489-2497.	0.6	63
34	Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification. <i>Journal of the American College of Surgeons</i> , 2013, 217, 324-335.	0.2	59
35	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672.	2.2	57
36	The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). <i>Annals of Surgical Oncology</i> , 2020, 27, 15-21.	0.7	56

#	ARTICLE	IF	CITATIONS
37	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. <i>Frontiers in Oncology</i> , 2014, 4, 110.	1.3	51
38	Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1012-1018.	0.7	49
39	Active Macromolecule Uptake by Lymph Node Antigen-Presenting Cells: A Novel Mechanism in Determining Sentinel Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2000, 7, 98-105.	0.7	48
40	Predictors of Occult Nodal Metastasis in Patients With Thin Melanoma. <i>Archives of Surgery</i> , 2010, 145, 137.	2.3	48
41	Staging of Regional Lymph Nodes in Melanoma. <i>JAMA Surgery</i> , 2013, 148, 879.	2.2	48
42	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. <i>Cancers</i> , 2019, 11, 1642.	1.7	47
43	A 20-Year Experience of Hepatic Resection for Melanoma: Is There an Expanding Role?. <i>Journal of the American College of Surgeons</i> , 2014, 219, 62-68.	0.2	41
44	Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND). <i>Annals of Surgery</i> , 2017, 265, 192-196.	2.1	39
45	Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. <i>International Journal of Cancer</i> , 2018, 142, 561-572.	2.3	37
46	Melanoma Vaccines. <i>Surgical Clinics of North America</i> , 2014, 94, 1017-1030.	0.5	36
47	Solitary Dermal Melanoma: Beginning or End of the Metastatic Process?. <i>Annals of Surgical Oncology</i> , 2009, 16, 578-584.	0.7	34
48	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210.	1.0	33
49	<i>Mycobacterium bovis</i> Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function. <i>Frontiers in Immunology</i> , 2017, 8, 965.	2.2	32
50	Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 9-18.	0.2	30
51	Surgery and Sentinel Lymph Node Biopsy. <i>Seminars in Oncology</i> , 2007, 34, 498-508.	0.8	29
52	A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients. <i>Cancer Investigation</i> , 2007, 25, 285-293.	0.6	28
53	The prognostic importance of scalp location in primary head and neck melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 337-343.	0.8	28
54	Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments. <i>American Surgeon</i> , 2015, 81, 1005-1009.	0.4	26

#	ARTICLE	IF	CITATIONS
55	Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. <i>Annals of Surgical Oncology</i> , 2019, 26, 2254-2262.	0.7	26
56	Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by <i>Mycobacterium bovis</i> Bacille Calmette-Guérin. <i>Frontiers in Oncology</i> , 2017, 7, 61.	1.3	24
57	Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. <i>Annals of Surgical Oncology</i> , 2017, 24, 952-959.	0.7	23
58	The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 139-157.	1.7	23
59	Use of Gastrostomy and Combined Gastrojejunostomy Tubes for Enteral Feeding. <i>World Journal of Surgery</i> , 1999, 23, 603-607.	0.8	22
60	Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 158-164.	2.5	22
61	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2089-2094.	0.7	22
62	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
63	Can Surgical Therapy Alone Achieve Long-Term Cure of Melanoma Metastatic to Regional Nodes?. <i>Cancer Journal (Sudbury, Mass )</i> , 2006, 12, 207-211.	1.0	20
64	Management of Popliteal Sentinel Nodes in Melanoma. <i>Journal of the American College of Surgeons</i> , 2011, 213, 180-186.	0.2	20
65	Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 225, 302-311.	0.2	20
66	Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 4610-4618.	0.7	20
67	Parathyroidectomy for Patients With Primary Hyperparathyroidism and Associations With Hypertension. <i>JAMA Surgery</i> , 2020, 155, 32.	2.2	19
68	Evolving Therapeutic Strategies in Mucosal Melanoma Have Not Improved Survival Over Five Decades. <i>American Surgeon</i> , 2016, 82, 1-5.	0.4	18
69	Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 3313-3319.	1.3	17
70	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 312-320.	0.6	17
71	Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. <i>Journal of the American College of Surgeons</i> , 2016, 222, 253-260.	0.2	16
72	Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 431-442.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	2.1	16
74	A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6126-6137.	0.7	16
75	Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes?. <i>Journal of the American College of Surgeons</i> , 2017, 225, 149-158.	0.2	13
76	Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. <i>American Surgeon</i> , 2016, 82, 1009-1013.	0.4	13
77	Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. <i>Leukemia Research</i> , 2000, 24, 795-804.	0.4	12
78	Radiofrequency Ablation of Hepatic Malignancies: Inexpensive and Minimally Invasive but Should It Replace Resection?. <i>Annals of Surgical Oncology</i> , 2003, 10, 1002-1004.	0.7	12
79	Sentinel-Node Biopsy in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 2148-2150.	13.9	11
80	Attitudes and Perceptions of Surgical Oncology Fellows on ACGME Accreditation and the Complex General Surgical Oncology Certification. <i>Annals of Surgical Oncology</i> , 2015, 22, 3776-3784.	0.7	11
81	Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41.	0.7	11
82	Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments. <i>American Surgeon</i> , 2015, 81, 1005-9.	0.4	11
83	Melanoma: is immunotherapy of benefit?. <i>Advances in Surgery</i> , 2003, 37, 139-69.	0.6	11
84	Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of american joint committee on cancer stage III melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 85-93.	0.7	10
85	Does specialized surgical training increase lymph node yield in colon cancer?. <i>American Surgeon</i> , 2009, 75, 887-91.	0.4	10
86	Response to Comment on "Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Staging. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e104-e105.	2.1	9
87	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	0.7	8
88	Epitrochlear sentinel lymph nodes in melanoma: interval or independent?. <i>American Surgeon</i> , 2012, 78, 702-5.	0.4	8
89	Completing the Dissection in Melanoma: Increasing Decision Precision. <i>Annals of Surgical Oncology</i> , 2018, 25, 585-587.	0.7	7
90	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>European Journal of Surgical Oncology</i> , 2022, 48, 1280-1287.	0.5	7

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Multiple Draining Lymph Node Basins in Melanoma: A Matched-Pair Analysis Based on the John Wayne Cancer Institute Experience. <i>Frontiers in Oncology</i> , 2017, 7, 172.	1.3	6
92	Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. <i>Cancer Medicine</i> , 2021, 10, 4302-4311.	1.3	6
93	The Promise of Metastasectomy in Melanoma. <i>Annals of Surgical Oncology</i> , 2006, 13, 607-609.	0.7	5
94	Current Surgical Treatment in Melanoma. <i>Current Problems in Cancer</i> , 2011, 35, 173-184.	1.0	5
95	More on Adjuvant Therapy in Resected Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1656-1657.	13.9	5
96	Survival and the Sentinel Lymph Node in Melanoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 18-20.	0.7	4
97	Sentinel Lymph Node Biopsy for Melanoma: A Plea to Let the Data be Heard. <i>Annals of Surgical Oncology</i> , 2014, 21, 3362-3364.	0.7	4
98	Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram". <i>Journal of Clinical Oncology</i> , 2020, 38, 3233-3234.	0.8	4
99	Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2706-2708.	0.8	4
100	Quantitative Nodal Burden and Mortality Across Solid Cancers. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1003-1011.	3.0	4
101	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	4
102	Dendritic cells in melanoma immunotherapy. <i>Current Treatment Options in Oncology</i> , 2005, 6, 175-184.	1.3	3
103	Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed. <i>Annals of Surgical Oncology</i> , 2018, 25, 3416-3418.	0.7	3
104	Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma". <i>Journal of the American Academy of Dermatology</i> , 2023, 88, e25-e26.	0.6	3
105	Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. <i>Annals of Surgical Oncology</i> , 2020, 27, 1970-1977.	0.7	3
106	Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. <i>Melanoma Research</i> , 2021, 31, 378-388.	0.6	3
107	Sentinel Lymph Node Biopsy. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 401-414.	0.6	3
108	Staging of Regional Nodes in Pulmonary Malignancies. <i>Annals of Surgical Oncology</i> , 2012, 19, 703-705.	0.7	2

#	ARTICLE	IF	CITATIONS
109	Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 419-421.	0.6	2
110	ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?. <i>Annals of Surgical Oncology</i> , 2019, 26, 4619-4620.	0.7	2
111	Donald L. Morton Memorial Lecture: the legacy of Donald Morton: past, present and future. <i>Clinical and Experimental Metastasis</i> , 2021, , 1.	1.7	2
112	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021, 43, 539-541.	0.3	2
113	381â€¦Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. , 2021, 9, A415-A415.		2
114	Melanoma trials that defined surgical management. <i>Journal of Surgical Oncology</i> , 2022, 125, 34-37.	0.8	2
115	From the Guest Editor. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 1-2.	1.0	1
116	Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?. <i>Annals of Surgical Oncology</i> , 2020, 27, 2586-2588.	0.7	1
117	Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. <i>JAMA Surgery</i> , 2021, 156, e214298.	2.2	1
118	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
119	Reply to Letter to the Editor â€œLymphoedema in the Observation and Biopsy Arms of MSLT-1â€ by Thomas, J Meirion (ASO-2011-04-0666). <i>Annals of Surgical Oncology</i> , 2011, 18, 312-314.	0.7	0
120	Regarding complications following completion lymphadenectomy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2374-2375.	0.5	0
121	ASO Author Reflections: The Past, Present, and Future of Managing Melanoma Lymph Node Metastases: What the Trials Tell Us. <i>Annals of Surgical Oncology</i> , 2020, 27, 735-736.	0.7	0
122	Survival impact of sentinel lymphadenectomy. <i>Expert Review of Dermatology</i> , 2009, 4, 5-8.	0.3	0
123	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0
124	ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
125	ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
126	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0